Cargando…
Mibefradil alters intracellular calcium concentration by activation of phospholipase C and IP(3) receptor function
Mibefradil is a tetralol derivative originally developed as an antagonist of T-type voltage-gated calcium (Ca(2+)) channels to treat hypertension when used at nanomolar dosage. More recently, its therapeutic application in hypertension has declined and has been instead repurposed as a treatment of c...
Autores principales: | Souza Bomfim, Guilherme H., Mitaishvili, Erna, Aguiar, Talita Ferreira, Lacruz, Rodrigo S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Singapore
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607413/ https://www.ncbi.nlm.nih.gov/pubmed/35006468 http://dx.doi.org/10.1186/s43556-021-00037-0 |
Ejemplares similares
-
Calcium Transport in Specialized Dental Epithelia and Its Modulation by Fluoride
por: Costiniti, Veronica, et al.
Publicado: (2021) -
Mibefradil reduces blood glucose concentration in db/db mice
por: Lu, Yujie, et al.
Publicado: (2014) -
Mitochondrial Function in Enamel Development
por: Costiniti, Veronica, et al.
Publicado: (2020) -
Creation of a new class of radiosensitizers for glioblastoma based on the mibefradil pharmacophore
por: Paradkar, Sateja, et al.
Publicado: (2021) -
Mibefradil and Flunarizine, Two T-Type Calcium Channel Inhibitors, Protect Mice against Lipopolysaccharide-Induced Acute Lung Injury
por: Wan, Limei, et al.
Publicado: (2020)